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OBJECTIVES: ‘Daytime functioning’ is a widely used outcome to describe quality of 
patients’ functional performance during daytime and gaining popularity as an efﬁcacy 
outcome in pharmaceutical interventions. The purpose of this study was to conduct 
a review of the literature and identify studies and patient-reported outcome instru-
ments that purport to measure daytime functioning. METHODS: A search was con-
ducted of the English-language studies published between January 1950 and June 2008 
using Medline. Key terms used were ‘daytime function and questionnaires’, ‘daytime 
functioning and quality of life’, ‘daytime functioning and questionnaires’, and ‘daytime 
functioning and quality of life’. Studies that observed functional performance from 
adult population were exclusively selected and of those articles, patient-reported 
questionnaires were identiﬁed. Validity of instruments was assessed based on reported 
psychometric properties. RESULTS: Total of 55 articles were identiﬁed. Studied 
patient population had sleep disorders (including apnea) (n  47), cancer (n  2), 
restless leg syndrome (n  2), allergic rhinitis (n  1), Alzheimer’s disease (n  1), coro-
nary artery disease (n  1), overactive bladder (n  1), and Parkinson’s disease (n  
1). Of these, 45% (n  25) articles included a patient-reported outcome questionnaire 
that claimed to measure daytime functioning. The remaining articles (55% n  30) 
included objective measurement to describe daytime function performance or used 
questionnaires without the supporting evidence of reliability, validity and interpret-
ability. After excluding duplicated PRO-questionnaires, 13 tools were identiﬁed and 
changes in patients’ functioning were observed from different areas; generic disease 
state (i.e. health, social support and activities survey) (n  4), sleep disorders (n  4), 
psychiatry (n  3) and fatigue (n  1). CONCLUSIONS: Not all studies that purport 
to measure daytime functioning used validated PRO tools to measure changes in 
daytime functioning. The criteria of deﬁning daytime functioning were differed among 
different disease states. Future studies that will investigate the domain of daytime 
functioning, it is recommended to select appropriate validated PRO instruments that 
can support the intended claim.
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OBJECTIVES: To evaluate the factors driving selection of the primary medication for 
multiple sclerosis (MS) by patients. METHODS: Baseline data from ROBUST, which 
is a 12-month, US prospective, observational, open-label, single-arm, multi-center 
outcomes study of Interferon B-1b given every other day for relapsing forms of 
MSwere analyzed. At baseline, patients were asked to rate the importance of factors 
that are typically considered before making a decision to select the primary medication 
to treat MS (on a scale of 1  not at all important through 5  very important). Twelve 
factors were evaluated: how well medication works, how much medication is given 
per dose, convenience of taking medication, convenience of storing medication, fre-
quency of administration, information in product decision kit, injection needle of the 
medication, personal research, doctor recommendation, family opinion, opinion of 
other MS patients and recommendation of MS advocacy groups. Mean scores on each 
factor were compared across patient sociodemographic characteristics, primary medi-
cation types and disease severity. RESULTS: At baseline, a total of 99 reported taking 
medication to treat their MS and thus provided responses on the items of interest. In 
this sample, 80.8% were females, 61.6% married, 70.4% below 50 years old and 
82.8% White. Among all patients, the highest importance scores were received for 
how well the medications controls MS progression (Mean [95% Conﬁdence Interval] 
 4.72 [4.57–4.86]) followed by their doctor’s recommendation (4.57 [4.41–4.72]), 
the convenience of taking the medications (3.88 [3.63–4.13]), personal research (3.81 
[3.56–4.05]) and the convenience of storing the medication (3.71 [3.44–3.98]). 
These factors and their order of importance remained consistent across patient 
sociodemographic characteristics, primary medication types and disease severity. 
CONCLUSIONS: Contributing to the limited published research about factors 
 considered by patients when selecting primary medication for their MS, this analysis 
found that medication effectiveness to control MS progression and doctor 
recommendation are the most important drivers of medication selection.
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OBJECTIVES: To explore the association of baseline health-related quality of life 
(HRQoL) and clinical measures of disability and motor functioning in a real-world 
observational study of multiple sclerosis (MS) patients. METHODS: The Real-World 
Betaseron® Outcomes Study (ROBUST) is a US, prospective, 12-month, observational, 
single-arm, open-label, multi-center outcomes study of interferon beta-1b given every 
other day for MS. A total of 226 patients were registered at 52 neurologists’ sites. 
Clinical measures and patient outcomes were reported by physicians and patients via 
a web-based data capture tool. The Kurtzke Expanded Disability Status Scale (EDSS) 
and Timed 25-foot Walk (T25FW; in seconds) were measured by the neurologist at 
baseline to evaluate patient disability and motor functioning. HRQoL was measured 
at baseline for 191 patients via the SF-12 Health Survey. For this analysis, EDSS and 
T25FW were categorized into ﬁve (0, 1–2, 2.5–4, 4.5–5.5, 6) and two (  7, 7 sec) 
groups, respectively. SF-12 results were summarized by Physical Component Score 
(PCS-12) and Mental Component Score (MCS-12). Analysis of variance methods were 
used to explore the association of baseline HRQoL and clinically measured EDSS and 
T25FW. RESULTS: At higher EDSS scores (i.e., worsening disability), both physical 
and mental HRQoL were lower; however, this association was only statistically sig-
niﬁcant for PCS-12 (p   .001 for PCS-12, p  0.707 for MCS-12). For PCS-12, 
among adjacent EDSS groups, pairwise differences were statistically signiﬁcant between 
EDSS  1–2 vs. EDSS  2.5–4 (44.0 vs. 37.2; p  .0004), suggesting a marked worsen-
ing of physical HRQoL at or above the disability threshold of EDSS  2.5. Both PCS-12 
and MCS-12 were higher for the group with better ambulation: T25FW   7 sec vs. 
T25FW 7 sec (43.5 vs. 37.0, p  0.001 for PCS-12; 43.9 vs. 41.0, p  0.079 for 
MCS-12). CONCLUSIONS: Physical HRQoL is associated with functional impair-
ment assessed via the EDSS and T25FW. This suggests that the PCS-12 component 
of the generic HRQoL tool reﬂects clinical functional impairment in MS patients.
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OBJECTIVES: Health related quality of life (HrQoL) is an important outcome in 
multiple sclerosis (MS). As part of the measurement system “Functional Assesment of 
Chronic Illness Therapy (FACIT)” targeted to the management of chronic illnesses, 
the Functional Assessment of MS (FAMS) is a self-reported questionnaire assessing 
patient-reported treatment effects in MS studies. Although the FAMS is validated in 
MS, the link between meaningful clinical efﬁcacy and FAMS score changes remains 
unclear. Objective was to determine anchor-based “clinical important differences” 
(CID) in FAMS total score (FAMS TS) and FAMS trial outcome index (FAMS TOI) 
using disability as measured by the Expanded Disability Status Scale (EDSS). 
METHODS: 6 months data from a prospective, observation study (BetaPlus) in 
patients with relapsing MS were used. All patients had been switched from another 
drug to interferon beta-1b 1–3 months before inclusion. The EDSS, the FAMS-TS, the 
FAMS-TOI were assessed at baseline and 6 months, with 1078 respondents at baseline 
and 950 at follow-up. Regression analysis was used to estimate CID of FAMS change 
scores by three anchor categories of EDSS change (“deteriorated”, “unchanged”, 
“improved”). Distribution based measures (standardized effect size (SRM)) were used 
to quantify the strength of CID. RESULTS: CID at 6 months was 5.65 [95% conﬁ-
dence interval: 0.75;10.56] (FAMS TS) and 4.22 [0.02;8.42] (FAMS TOI). All coefﬁ-
cients for “EDSS improved” were signiﬁcantly larger than for “EDSS unchanged” with 
SRM of 0.24 and 0.23, respectively. CONCLUSIONS: CID estimates are provided 
for improvement in HRQOL in patients with MS over a six-month period. The results 
are inline with published CID of FACIT instruments ranging from 4 to 8 units in 
patients with cancer. The estimated CID can assist clinicians and health policy makers 
in evaluating signiﬁcance of short-term treatment effects of medical as well as non-
medical interventions (e.g. patient support programmes).
PND38
COSTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH 
GILLES DE LA TOURETTE’S SYNDROME
Balzer-Geldsetzer M1, Müller-Vahl K2, Dodel I1, Reese JP1, Oertel WH1, Dodel R1
1Philipps University, Marburg, Germany, 2Hannover Medical School, Hannover, Germany
OBJECTIVES: To assess the costs and the health-related quality of life (HrQoL) of 
patients with Gilles de la Tourette’s syndrome (GTS) in Germany METHODS: Direct 
and indirect costs as well as HrQoL were evaluated in 200 patients with GTS in three 
outpatient departments in Germany. Economic data was provided in a patient diary 
over a three-months-period. Costs were analyzed from the perspective of the statutory 
health insurance. Indirect costs were calculated by the human capital approach. 
HrQoL was measured using the EuroQol instrument. Depression was assessed using 
the Beck Depression Inventory (BDI) and clinical symptoms with the Yale Tourette 
Syndrome Symptom list (YTSSL) and the Shapiro-Tourette-Syndrome-Severity-Scale 
(STSSS). RESULTS: Direct costs amounted to a635 during the evaluation period. 
Indirect costs totalled to a2500. Major cost components were: drug costs (a350) and 
in-stays (a300). Patients with GTS proved to have a worse HrQoL than a representa-
tive sample of the general German population. In GTS patients the most affected 
EQ-5D domains were anxiety/depression (57.1%), pain/discomfort (47.5%), and daily 
activities (38.4%). The mean EQ VAS score was 65.4 o 21.9. The patients had a mean 
BDI score of 12.3 o 9.9, which was considerably worse compared to a representative 
German sample with a mean BDI score of 6.45 o 5.2. The mean STSSS value was 
3.24 o 1.1. There was no signiﬁcant difference between genders with respect to tic 
severity. A signiﬁcant correlation for BDI, age, YTSSL, STSSS, subjective efﬁcacy of 
